NOILE-IMMUNE BIOTECH INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 213 JPY | -9.75% |
|
+42.00% | +0.47% |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 10,219 | - | - |
| Enterprise Value (EV) 1 | 10,219 | 10,219 | 10,219 |
| P/E ratio | -12 x | -11.6 x | -11.3 x |
| Yield | - | - | - |
| Capitalization / Revenue | 32 x | 32 x | 32 x |
| EV / Revenue | 32 x | 32 x | 32 x |
| EV / EBITDA | -12 x | -11.7 x | -11.3 x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 43,302 | - | - |
| Reference price 2 | 236.0 | 236.0 | 236.0 |
| Announcement Date | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | 625.8 | 319 | 319 | 319 |
| EBITDA 1 | - | -850 | -876 | -904 |
| EBIT 1 | - | -849.5 | -876.2 | -904 |
| Operating Margin | - | -266.3% | -274.67% | -283.39% |
| Earnings before Tax (EBT) 1 | - | -850 | -876 | -904 |
| Net income 1 | -386.6 | -851 | -877 | -905 |
| Net margin | -61.78% | -266.77% | -274.92% | -283.7% |
| EPS 2 | - | -19.65 | -20.27 | -20.90 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 13/03/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 13/03/23 | - | - | - |
1JPY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
236
JPY
Average target price
440
JPY
Spread / Average Target
+86.44%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.47% | 65.8M | |
| +16.93% | 124B | |
| +17.01% | 109B | |
| -7.23% | 23.84B | |
| +1.98% | 22.42B | |
| -14.29% | 17.5B | |
| -6.79% | 16.61B | |
| -37.63% | 16.43B | |
| +2.17% | 13.4B | |
| +24.42% | 11.47B |
- Stock Market
- Equities
- 4893 Stock
- Financials Noile-Immune Biotech Inc.
